Invasive salivary duct carcinoma ex pleomorphic adenoma of the parotid gland: a teaching case giving rise to the genuine diagnostic difficulty on an inadequate cytology specimen
© Yamada et al.; licensee BioMed Central Ltd. 2012
Received: 15 March 2012
Accepted: 23 April 2012
Published: 30 May 2012
A history of a recent rapid increase in long-standing swelling mass was presented in the right parotid gland of an 85-year-old male. The inadequate cytologic specimens contained few small clusters of three-dimensional malignant epithelial cells having hyperchromatic pleomorphic nuclei and prominent nucleoli, adjacent to a cluster of benign monomorphic myoepithelial cells. We first interpreted it merely as an adenocarcinoma, not otherwise specified. A radical parotidectomy was performed, and gross examination revealed an encapsulated and firm tumor lesion, looking grayish-blue to yellowish-white, focally associated with extracapsular invasion. On microscopic examination, the tumor was predominantly composed of a proliferation of highly atypical epithelial cells having abundant eosinophilic cytoplasm, often arranged in a Roman-bridge appearance with foci of comedo necrosis, alternating with extensive infiltration to adjacent stroma in a trabecular or alveolar fashion with severe vessel permeation. Within the background of pleomorphic adenoma, the carcinoma cells sometimes replaced ductal luminal cells while retaining an intact-like myoepithelial layer. Therefore, we finally made a diagnosis of invasive salivary duct carcinoma ex pleomorphic adenoma. We should be aware that owing to its characteristic features, cytopathologists might be able to determine correct diagnosis, based on multiple and adequate samplings.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2126158270695815
KeywordsSalivary duct carcinoma Carcinoma ex pleomorphic adenoma Salivary gland Cytology
Among all salivary gland neoplasms, carcinoma ex pleomorphic adenoma (Ca ex PA) accounts for approximately 3.6% , whereas constitutes 6.2% of all PA and 11.6% of all malignant salivary gland neoplasms [1, 2]. Despite of that, Ca ex PA is uncommon and has a prevalence rate of 5.6 cases per 100,000 malignant neoplasms and a yearly incidence rate of 0.17 tumors per 1 million people [1, 2]. This neoplasm is defined as an epithelial malignant transformation within a primary (de novo) or recurrent PA, and often poses a diagnostic challenge to clinicians and cytopathologists, since its entity is difficult to diagnose pre-operatively [3, 4]. In fact, Ca ex PA can be asymptomatic as most of them are not widely invasive on gross findings and often have similar clinical presentations as PA, however, patients with Ca ex PA have a poor prognosis due to infiltrative and destructive behavior, and thus, early and accurate diagnosis and aggressive surgical treatment (i.e., total or radical parotidectomy) can increase their survival rates [1–5]. Although any form of carcinoma can be observed and also be a mixture of subtypes, the malignant component of Ca ex PA is most often adenocarcinoma, not otherwise specified (NOS), and sometimes, may be salivary duct carcinoma (SDC), undifferentiated carcinoma, adenoid cystic carcinoma, or mucoepidermoid carcinoma [1, 2, 4, 6]. While, WHO states that its component is most frequently a poorly differentiated carcinoma, e.g., SDC or adenocarcinoma, NOS, or an undifferentiated carcinoma .
On the other hand, SDC was first described by Kleinsasser et al in 1968 , and to date, more than 100 cases have been reported and account for approximately 9% among all salivary gland neoplasms . SDC is a distinctive but relatively common high grade adenocarcinoma arising from the excretory ductal epithelium of the major salivary glands, especially the parotid gland [8–10]. Clinically, these tumors are characterized by aggressive (i.e., infiltrative and destructive) behavior with local recurrence, early and distant metastasis, invasion of the facial nerve, and/or significant mortality [8–11]. Histopathologically, SDCs have a striking resemblance to ductal carcinoma of the breast, exhibiting intraductal and infiltrating components [8, 10, 11]. In addition, very intriguingly, they should show a broader clinicopathological spectrum and many cases of them may develop within PA as a result of malignant transformation of ductal epithelial cells [9, 12]. It has been actually reported that multifocal origin of SDC from major excretory ducts surrounding a PA was found . By contrast, Simpson RHW et al. described that the majority of them arise de novo (as in the breast) probably from a pure in situ carcinoma . Similar to Ca ex PA, aggressive clinical management in the early stage of SDC appears to be the only hope for good prognosis [5, 6, 8–11]. Thus, it is critical to establish an accurate preoperative diagnosis by fine-needle aspiration cytology, however, previous studies have indicated the difficulty of correct characterization of Ca ex PA and/or SDC due to sampling errors or inadequateness and misinterpretation [14, 15].
In fact, invasive SDC ex PA could be relatively common disease, as compared with some recently published case reports of very rare tumor cell types in the salivary gland [16–18]. Despite of that, we report a case of SDC ex PA, which originated from the parotid gland and partially involved the surrounding soft tissue and lymph nodes as a rapidly increased but long-standing swelling mass. Based on the relatively inadequate cytology specimens, we preoperatively interpreted it merely as an adenocarcinoma, NOS.
Materials and methods
The patient was an 85-year-old Japanese man. A fine-needle aspiration from the parotid gland mass was performed, followed by a radical parotidectomy. The tumor specimens after fixation in 10% neutral buffered formalin were embedded in paraffin for histological or immunohistochemical examinations. All immunohistochemical stainings were carried out using Dako Envision kit (Dako Cytomation Co., Glostrup, Denmark) according to the manufacturer’s instructions. For transmission electron microscopy (JEM-1200EX, JEOL Ltd., Tokyo, Japan), the dehydrated tissue specimens, after fixed with 2.5% glutaraldehyde and immersed in 2% osmium tetroxide, were embedded in epoxy resin.
The patient had a history of benign prostatic hyperplasia 2 years ago. There was no history of malignancy, immunosuppressive disorders, use of immunosuppressive medications, or unusual infections.
He noticed a long-standing swelling mass in the right parotid gland and an enlargement of the neck lymph node 5 years before the resection. Following that, a recent rapid increase of them was presented. Laboratory data, including blood cell count, chemistry and tumor markers, were within normal limits. A neck CT scan revealed a heterogeneously enhanced and poorly-demarcated mass, measuring approximately 3 × 3 cm, in the right parotid gland. CT scans of the chest and abdomen disclosed no definite evidence of metastasis in the lymph nodes or other organs. The patient was alive and well at 8 months after the operation.
Ultrastructural findings of the transition areas from ‘intraductal’ to ‘extraductal’ components showed that the neoplastic columnar cells occasionally with luminal microvilli had enlarged irregular nuclei with dispersed chromatin and one or more prominent nucleoli, and cytoplasm containing not only a large amount of organelles, such as endoplasmic reticulum, but secretory-like granules (data not shown). The basally-located myoepithelial cells were seen, and were neoplastic-like with enlarged irregular nuclei and cytoplasmic dense bodies of myofilaments, intermingled with collagen bands (data not shown).
Immunohistochemical profile of the epithelial components in the invasive SDC ex PA
Based on all these features, we suggested that these proliferating carcinoma cells were characteristic of apocrine differentiation, and finally made a diagnosis of invasive SDC ex PA of the parotid gland.
Aggressive clinical treatment in the early stage for invasive SDC is the only hope for better prognosis, due to a high grade, malignant tumor, based on the infiltrative and destructive behavior [8–11]. Thus, it is critical to establish an accurate preoperative diagnosis by fine-needle aspiration cytology, the clinical utility of which in diagnosing salivary gland tumors has been generalized. The cytologic findings of invasive SDC reflect the histopathological ones resembling invasive ductal carcinoma of the breast, showing cohesive, three-dimensional clusters and flat sheets of large and polygonal atypical cells having abundant and finely granular cytoplasm, and prominent nucleoli, arranged in an irregular branching, cribriform, or papillary growth pattern as well as single cells formation in the background of frequent necrosis [15, 19]. Additionally, smears from Ca ex PA show moderate to high cellularity with pleomorphic malignant cells in the background of biphasic components of PA, displaying sheets of benign monomorphic epithelial cells along with metachromatic, fibrillary and myxoid or chondroid stroma . As in the current case, although the specimens were inadequate, the cytologic features were almost similar to those as described above, even while neither necrotic backgrounds nor any cribriform formations were observed. Despite that, a confident and accurate diagnosis of SDC ex PA was impossible on cytology, suggestively due to sampling errors, lack of experience, cytomorphologic variety, and misinterpretation. Nevertheless, in cases with a strong clinical suspicion of Ca ex PA, such as ours, multiple fine needle aspiration should be performed and its suspicion should be raised to alert the pathologist, at the very least.
An immunohistochemical analysis indicates that AR and GCDFP-15 are highly and specifically expressed in more than 80% and 90% of patients with SDC, respectively, whereas ER and PgR, well known as common breast carcinoma markers, are very weakly or negatively stained [11, 20–22]. Actually, one paper proposed that, when the cytologic features of high grade adenocarcinoma with a variety of cell morphology are difficult to make an accurate diagnosis, immunostaining for AR and ER on cytologic smears would be very useful for the diagnosis of SDC .
On the other hand, the luminal SDC carcinoma cells rarely show immunohistochemical expression of S-100 protein and p63, whereas the ‘reminiscent’ benign myoepithelial cells reveal those strong expression in the ‘intraductal’ and PA components [9–11, 20–22], even while the lost of myoepithelial cells is occasionally seen in the transition areas from ‘intraductal’ to ‘extraductal’ components , as in our case. Indeed, myoepithelial cells can be considered as natural tumor suppressors, distinguishing between early and advanced malignant tumors in the transition from in situ to invasive carcinomas, and can rarely undergo malignancy. However, in the present case, the neoplastic-like enlarged myoepithelial cells in the transition areas were sometimes negative for the above myoepithelial markers. These features indicate that those cells would not have apparent myoepithelial phenotypes, but potentially neoplastic character, probably confirmed by the ultrastructural findings. We could provide the evidence for the first time that invasive SDC ex PA may arise within or from PA as a result of neoplastic transformation of outer supporting myoepithelial cells, as well as inner ductal epithelial cells. Despite of that, future studies will be further required to determine whether our suggestion is significant after collecting and examining a larger number of its cases.
We herein reported a case of an invasive SDC ex PA. The present case was tentatively diagnosed as adenocarcinoma, NOS on the examination of the cytology, because its smears showed the inadequate and few components of malignant cells. All cytopathologists should be aware that its clinically and immunohistochemically characteristic features, as well as multiple and adequate fine needle aspiration, could lead to a correct diagnosis.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Gnepp DR: Malignant mixed tumours of the salivary glands: a review. Pathol Annu. 1993, 28: 279-328.PubMed
- Antony J, Gopalan V, Smith RA, Lam AK: Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data. Head Neck Pathol. 2011 Jul 09
- Gnepp DR, Brandwein-Gensler MS, El-Naggar AK, Nagao T: Carcinoma ex pleomorphic adenoma. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. Edited by: Barnes L, Eveson JW, Reichart P, Sidransky D. 2005, Lyon, France: IARC Press, 242-243.
- Ellis GL, Auclair PL: In: Tumors of the Salivary Glands. Atlas of tumor pathology. Carcinoma ex pleomorphic adenoma. 2008, Washington, D.C: Armed Forces Institute of Pathology, 259-269.
- Altemani A, Martins MT, Freitas L, Soares F, Araújo NS, Araújo VC: Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology. 2005, 46: 635-641. 10.1111/j.1365-2559.2005.02157.x.View ArticlePubMed
- Lewis JE, Olsen KD, Sebo TJ: Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol. 2001, 32: 596-604. 10.1053/hupa.2001.25000.View ArticlePubMed
- Kleinsasser O, Klein HJ, Hubner G: Speinchelgangcarcinome, ein den Milchegangcarcinomen der Brustdruse, analoge Gruppe von Speicheldrusentumoren. Archiv klein exper. Ohren-, Nasen- und Kehlkopfheilk. 1968, 192: 100-115. 10.1007/BF00301495.View Article
- Brandwein-Gensler MS, Skalova A, Nagao T: Salivary duct carcinoma. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. Edited by: Barnes L, Eveson JW, Reichart P, Sidransky D. 2005, Lyon, France: IARC Press, 236-237.
- Delgado R, Vuitch F, Albores-Saavedra J: Salivary duct carcinoma. Cancer. 1993, 72: 1503-1512.PubMed
- Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD: Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996, 77: 223-230. 10.1002/(SICI)1097-0142(19960115)77:2<223::AID-CNCR1>3.0.CO;2-N.View ArticlePubMed
- Ellis GL, Auclair PL: In: Tumors of the Salivary Glands. Atlas of tumor pathology. Salivary duct carcinoma. 2008, Washington, D.C: Armed Forces Institute of Pathology, 322-332.
- Brandwein MS, Jagirder J, Patil J, Biller H, Kaneko M: Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts): a clinicopathologic and immunohistochemical study of 12 cases. Cancer. 1990, 65: 2307-2314. 10.1002/1097-0142(19900515)65:10<2307::AID-CNCR2820651024>3.0.CO;2-1.View ArticlePubMed
- Simpson RHW, Desai S, Palma SD: Salivary duct carcinoma in situ of the parotid gland. Histopathology. 2008, 53: 416-425. 10.1111/j.1365-2559.2008.03135.x.View ArticlePubMed
- Nigam S, Kumar N, Jain S: Cytomorphologic spectrum of carcinoma ex pleomorphic adenoma. Acta Cytol. 2004, 48: 309-314. 10.1159/000326378.View ArticlePubMed
- Garcia-Bonafe M, Catala I, Tarragona J, Tallada N: Cytologic diagnosis of salivary duct carcinoma: a review of seven cases. Diagn Cytopathol. 1998, 19: 120-123. 10.1002/(SICI)1097-0339(199808)19:2<120::AID-DC11>3.0.CO;2-H.View ArticlePubMed
- Shin-ichi Nakatsuka, Hiroshi Harada, Hiroshi Fujiyama, Koji Takeda, Koji Kitamura, Hayato Kimura, Teruaki Nagano, Mahito Ito, Yuji Asada: An invasive adenocarcinoma of the accessory parotid gland: a rare example developing from a low-grade cribriform cystadenocarcinoma?. Diagn Pathol. 2011, 6: 122-10.1186/1746-1596-6-122.View Article
- Schraven Sebastian P, Plontke Stefan K, Roland Syha, Falko Fend, Hartwig Wolburg, Patrick Adam: Dendritic cell tumor in a salivary gland lymph node: a rare differential diagnosis of salivary gland neoplasms. Diagn Pathol. 2011, 6: 94-10.1186/1746-1596-6-94.PubMed CentralView ArticlePubMed
- Bersch C, Back W: Primary sebaceous adenoma of the salivary glands? a rare differential diagnosis: report of a case. Diagn Pathol. 2007, 2 (Suppl 1): S16-10.1186/1746-1596-2-S1-S16.View Article
- Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M: Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer (Cancer Cytopathology). 2001, 93: 344-350.
- Kapadia SB, Barnes L: Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998, 11: 1033-1038.PubMed
- Fan CY, Wang J, Barnes EL: Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000, 24: 579-586. 10.1097/00000478-200004000-00014.View ArticlePubMed
- Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK: Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007, 31: 1645-1652. 10.1097/PAS.0b013e3180caa099.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.